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Diabetes Mellitus
and its Management
An Introductory Overview
Diabetes is one of the most prevalent chronic disorders worldwide. By
2010, the number of people with diabetes is expected to exceed 350
million1. Diabetic complications cause considerable morbidity in 5-
10% of these patients, with diabetic complications accounting for 4%
of hospital admissions2. Malta is no exception with statistics
gathered in 1987 indicating that 10% of adults aged 35 and over had
diabetes while another 13% had impaired glucose tolerance (IGT).
This problem is found in other Mediterranean island communities
(Cyprus, Sardinia, Sicily, Pantelleria) where a prevalence of 5% is
found3. Opportunities for interacting with the diabetic patient are
numerous and the pharmacist is ideally positioned to intervene with
the aim of optimising patient treatment. This review will deal with a
brief pathophysiology of diabetes and its complications, a good
knowledge of which is fundamental since it leads to a clear
understanding of the factors to be considered when choosing the
appropriate therapy for the individual patient.
Part 1 Pathophysiology, Classification,
Diagnosis and Complications
Back to Basics
Definition of diabetes
Diabetes mellitus may be defined as
a clinical syndrome characterised by
hyperglycaemia due to absolute or
relative deficiency of  insulin4. If not
treated, diabetes may lead to acute
hyperglycaemia (diabetic ketoacidosis
(DKA) or non ketotic hyperosmolar
coma) and, if long-standing, to late
complications leading to a reduced life
expectancy.
How does insulin maintain
a normal blood glucose?
Following food intake, a
homeostatic mechanism comes into
play which ensures that food is
appropriately stored for later use. In
response to food ingestion and the
ensuing direct stimulatory effect of
glucose and amino acids on pancreatic
ß cells, insulin is secreted. This
promotes carbohydrate uptake by the
liver and muscle for glycogen synthesis,
carbohydrate uptake by adipose tissue
for triglyceride synthesis, amino acid
uptake into liver and muscle and
triglyceride uptake by adipose tissue.
Throughout, insulin acts as an
‘anabolic’ hormone, that is, it promotes
synthesis of protein, glycogen and
triglycerides and prevents their
breakdown into the respective subunits.
In the fasting state, mobilisation of
stored energy is necessary and this is
accomplished by:
1.  reduced insulin secretion resulting
in the release of glucose from
glycogen stores in the liver and
muscle
2.  increased lipolysis during which
triglycerides are broken down into
free fatty acids. This is enhanced by
glucagon and other counter-
regulatory hormones.
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Table I
Characteristic Features of Type I and Type II diabetes(2,6)
Feature Type I diabetes Type II diabetes
Prevalence • 5-10% of diabetic population 90% of all diabetics
Age of onset • usually less than 30 years • usually over 40 years
Pancreatic function • no residual or very little • retain some pancreatic function
pancreatic function
Aetiology • though exact aetiology is unknown, • involves defects in insulin secretion,
presence of islet cell antibodies resistance to insulin, hepatic glucose output
indicate an autoimmune function
Family history • generally not strong • strong family history
Obesity • commonly not obese • commonly obese
Onset • usually sudden and patients • insidious and diagnosed during
present with ketoacidosis routine examination
What happens
if there is a lack of insulin?
When insulin secretion  is lacking,
one observes:
1.  a breakdown of stored triglycerides
and proteins resulting in catabolism
and the characteristic weight loss
seen in uncontrolled diabetes
2.  an excessive production of ketone
bodies leading to metabolic
acidosis. This results in DKA - an
acute decompensated state which
should be treated as a medical
emergency4,5.
Classification of diabetes.
The following is an overview of the
classification of diabetes :
A.  Primary diabetes: implying that
no underlying disease is present
• Type I: previously known as insulin
dependent diabetes mellitus (IDDM)
or juvenile diabetes
• Type II: previously known as non-
insulin dependent diabetes mellitus
(NIDDM) or adult-onset diabetes
• MODY: maturity onset diabetes of
the young
B.  Gestational diabetes: defined as
hyperglycaemia which is first
diagnosed during pregnancy (that
is, not in a previously known
diabetic)
Diagnosis and treatment  are
important since the excess maternal
glucose crossing the placenta may
result in excess foetal insulin secretion.
This, in turn, may cause foetal
macrosomia and increase the risk of
birth trauma, may necessitate
Caeserean section and may lead to
neonatal hypoglycaemia. Women with
gestational diabetes often develop
diabetes within five years post partum4.
C.  Secondary diabetes: implying
diabetes secondary to an
underlying pathology
• Malnutrition related diabetes
• Secondary to pancreatic disease -
for example, chronic pancreatitis: a
common cause is alcoholism where
beta cell mass is destroyed6; cystic
fibrosis; neoplastic disease
• Secondary to endocrine disease -
often involves excess endogenous
production of hormonal antagonists
to insulin4,6: for example,
phaeochromocytoma; acromegaly;
Cushing’s syndrome; ‘stress
hyperglycaemia’ following severe
burns, acute myocardial infarction
and other life threatening illnesses
(due to endogenous release of
glucagon and catecholamines)
• Drug induced - for example,
corticosteroids, loop and thiazide
diuretics; phenytoin
• Insulin receptor dysfunctionality -
hyperglycaemia occurs due to
quantitative or qualitative defects
in the insulin receptor or to
antibodies directed against it1,6.
• Inherited disorders - (diabetes plus)
for example, muscular dystrophies;
Down’s syndrome; Turner’s
syndrome7.
• Non-endocrine disorders - for
example, renal failure and hepatic
failure
Type I and Type II diabetes are the
most commonly encountered forms of
diabetes and consequently, this review
will focus mainly on these two types.
Since the approach to management and
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treatment is somewhat different, an
understanding of the main features of
each one and the differences between
the two is crucial.
Table 1 summarises the main
characteristic features of Type I and
Type II diabetes1,6:
What  are  the signs and
symptoms of diabetes?
It is of primary importance that the
pharmacist has a good understanding
of commonly presenting signs and
symptoms of diabetes since patients
may present at the community
pharmacy with such ailments.
In the Type I patient, the onset of
the disease is sudden with profound
weight loss (despite increased intake
of food), severe fatigue, polydipsia
(thirst) and polyuria (frequent
urination) 5,8. Such patients should be
referred immediately since acute
metabolic decompensation is imminent
and patients normally require
hospitalisation.
Patients with Type II present with
less severe symptoms - fatigue,
polyuria and vaginal and urinary tract
infections. However, the onset of Type
II is often a gradual process and very
often the ‘classic’ symptoms are not
apparent. Therefore, patients may
present when complications of diabetes
have occurred8. It is therefore very
important to encourage patients at
high risk to undergo screening tests
with emphasis on fasting and random
blood glucose levels.
The World Health Organisation
criteria for the diagnosis of diabetes
mellitus are5,9:
1.  A fasting blood glucose of >7.8
mmol/l preferably obtained on two
repeated occasions or a random
blood glucose of >11.1 mmol/l on
two repeated occasions
2.  A two hour glucose level of 11.1
mmol/l or more during an oral
glucose tolerance test. When the
two hour value is between 7.8 and
11.1 mmol/l, the patient is
diagnosed as having IGT. This
implies that the patient is:
• at an increased risk of developing
diabetes
• at an increased risk of developing
atherosclerotic disease.
When IGT is diagnosed, management
is directed toward avoidance of
diabetes and arterial disease - follow up
with blood glucose tests is imperative.
At this point, it is appropriate to
mention urine testing for glucose.
Unfortunately, there is a popular
local belief that urine testing for
glucose is “THE TEST” to use to
diagnose and monitor diabetes. Urine
glucose concentrations correlate poorly
with blood glucose concentrations and
therefore should only be used for
patients who cannot or refuse to test
blood. In the healthy individual, a blood
glucose of 15 mmol/l or over is required
for a urine glucose test to be positive.
Besides, the renal threshold for glucose
may be decreased, as in pregnancy or
when other sugars are present in the
urine, or increased in the elderly. This
results in false positive or false negative
tests implying that urine testing is not
a reliable method5.
Why is it important to
maintain normal glucose
levels?
The main aim of trying to achieve
euglycaemia (normal blood glucose
levels) is to prevent development of
acute complications and to delay
progression of the disease. Published
studies have provided evidence that
tight glycaemic control is associated
with reduced complications both in Type
I and Type II. The Diabetes Control and
Complication Trial (DCCT) has clearly
shown this in Type I diabetes10 while
the UK Prospective Diabetes Study
(UKPDS) has shown this in Type II
diabetes11. The latter is the longest and
largest study in the history  of  diabetes
and has clearly shown that tight control
produced a 25% reduction of
macrovascular complications9.
The main chronic
complications of diabetes
A.  Macrovascular disease: This leads
to an increased risk of coronary
heart disease and is the major cause
of increased mortality in diabetic
patients accounting for about 70%
of all deaths4. Risk factors for
coronary heart disease (for example,
smoking, hypertension and
hypercholesterolaemia) have to be
minimised in a diabetic patient
since risk factors are additive5.
B.  Diabetic microangiopathy: This is
a disease of the small vessels
specific to diabetes. It is the main
cause of morbidity in the diabetic
patient. Diabetes first induces a
structural abnormality in the blood
vessel with an increase in basement
membrane thickness. This
consequently leads to a functional
abnormality with increased
permeability of the blood vessels to
fluid and molecules such as
albumin10. Though all blood vessels
are affected, three specialised
regions are at particular risk:
• the kidney, leading to diabetic
nephropathy
• the eye, leading to diabetic
retinopathy and blindness
• the nerve sheath, leading to
diabetic neuropathy in turn leading
to a loss of sensation and increased
risk of injury.
The acute complications
of diabetes
A.  Diabetic ketoacidosis (DKA): a
metabolic acidosis which occurs due
to  excess synthesis of ketone
bodies as a result of insulin
deficiency. As already explained
above, an insulin deficiency results
in a catabolic state where
triglycerides are broken down into
free fatty acids. These are taken up
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by the liver together with alanine,
lactate and glycerol to synthesise
acidic ketone bodies, acetoacetate
and 3-hydroxybutyrate.
Accumulation of these substances
leads to a metabolic acidosis. The
patients normally present with
profound dehydration,
hyperventilation, vomiting and
sometimes abdominal pain.
Management involves:
• Fluid replacement in the form of
0.9% normal saline
• Electrolyte replacement
• Insulin replacement usually in the
form of a continuous intravenous
infusion5.
Within the local state hospital, all
DKA patients are admitted on wards M5
and M6. A written protocol for the
treatment of DKA is present on the
wards and ensures that management is
standardised.
B.  Non-ketotic hyperosmolar coma:
This usually occurs in older patients
and normally affects patients with
Type II. It occurs when uncontrolled
hyperglycaemia leads to
dehydration, increased osmolality
and ultimately coma. However,
ketosis does not develop since some
residual insulin activity inhibits the
peripheral lipolysis occurring in DKA
and ketone production is therefore
suppressed. Patients normally
present with profound dehydration
and a reduced level of
consciousness. Management is
similar to that for DKA with the
exception of the following :
• Fluid replacement is in the form of
0.45% Normal saline
• Insulin replacement is usually less
• Due to the high risk of thrombosis,
heparin treatment is instituted12.
C.  Hypoglycaemia: This fall in blood
glucose is often related to
treatment issues in Type I and Type
II patients. This will be discussed in
detail later on in the series.  ✱
